Abstracts tagged "interstitial lung disease and myositis"

Abstract Number: 376 • 2018 ACR/ARHP Annual Meeting
Antisynthetase Syndrome: Prevalence of Serositis in Autoantibody Subsets
Alexis Katz¹, James Bena² and Soumya Chatterjee³, ¹Internal Medicine, Cleveland Clinic, Cleveland, OH, ²Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ³Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH
Background/Purpose: Antisynthetase Syndrome (AS) is a relatively rare autoimmune disease characterized by interstitial lung disease (ILD), myositis, inflammatory arthritis, Raynaud phenomenon, and mechanic’s hands. Eight autoantibodies (Ab) to…
Abstract Number: 392 • 2018 ACR/ARHP Annual Meeting
Autoantibody Profile and Clinical Characteristics in Patients with Idiopathic Inflammatory Myopathies
Sung Hae Chang¹, Sung Won Lee², Mi-Il Kang³, Mihye Kwon⁴, Chung-Il Joung⁴, Seong-Wook Kang⁵, In-Seol Yoo⁵, Seung-Cheol Shim⁵, Su-Jin Yoo⁶, In Ah Choi⁷, Ji Hyoun Kim⁸, Seung-Jae Hong⁹, Yeon-Ah Lee⁹, Sang Wan Chung¹⁰ and Jinhyun Kim¹¹, ¹Department of Internal Medicine, Department of Internal Medicine, College of Medicine, Soonchunhyang University, Cheonan, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Department of Rheumatology, Department of Internal Medicine, College of Medicine, Soonchunhyang University, Cheonan, Korea, Republic of (South), ³Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea, Republic of (South), ⁴Department of Internal Medicine, Konyang University hospital, Daejeon, Korea, Republic of (South), ⁵Division of Rheumatology, Department of Internal Medicine, Daejeon Rheumatoid & Degenerative Arthritis Center, Chungnam National University Hospital, Daejeon, Korea, Republic of (South), ⁶Rheumatology, Daejeon Rheumatoid & Degenerative Arthritis Center, Chungnam National University Hospital, Daejeon, Korea, Republic of (South), ⁷Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea, Republic of (South), ⁸Department of Internal Medicine, Chungbuk National University College of Medicine, Cheong-ju, Korea, Republic of (South), ⁹Rheumatology, Kyung Hee University Hospital, Seoul, Korea, Republic of (South), ¹⁰Division of Rheumatology, Department of Internal Medicine, Kyung Hee University Hospital, Seoul, Korea, Republic of (South), ¹¹Internal medicine, Daejeon Rheumatoid & Degenerative Arthritis Center, Chungnam National University Hospital, Deajeon, Korea, Republic of (South)
Background/Purpose: Autoimmune myositis (AIM) is a constellation of rare chronic disease with progressive muscle weakness. Several autoantibodies are found to be highly correlated with IIM…
Abstract Number: 396 • 2018 ACR/ARHP Annual Meeting
Clinical, Physiologic, and Radiologic Features Associated with Severe MDA5-Associated Interstitial Lung Disease
Tracy Doyle¹, Priya Borker², Elaine Fletcher¹, David Murphy³, Rachna Madan³ and Paul F. Dellaripa⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, Boston, MA, ³Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Autoantibodies against melanoma differentiation-associated protein 5 (MDA-5) have been described in patients with dermatomyositis (DM) and progressive interstitial lung disease (ILD). Previous cohorts have…
Abstract Number: 877 • 2018 ACR/ARHP Annual Meeting
Serum Krebs Von Den Lungen-6 Is a Useful Biomarker for Assessing Activity of Myositis-Associated Interstitial Lung Disease
Satoshi Takanashi¹, Naoshi Nishina², Maho Nakazawa², Yuko Kaneko² and Tsutomu Takeuchi², ¹Division of Rheumatoloy, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Interstitial lung disease (ILD) is one of serious organ involvements in idiopathic inflammatory myositis. Krebs von den Lungen-6 (KL-6) is an antigen produced primarily…
Abstract Number: 1310 • 2018 ACR/ARHP Annual Meeting
Diagnostic Utility of Myositis Antibodies in Patients with Interstitial Lung Disease and Suspected Underlying Connective Tissue Disease
Verónica Wolff¹, Juan Maya², Carolina Cuéllar³, Matías Florenzano¹, Alexis Peralta⁴ and Viviana Balboa⁴, ¹Rheumatic Lung diseases Unit, Instituto Nacional del Tórax, Santiago, Chile, ²Rheumatology Unit, Hospital del Salvador. Facultad de Medicina. Universidad de Chile, Santiago, Chile, ³Rheumatology Section, Hospital del Salvador, Universidad de Chile, SANTIAGO, Chile, ⁴Laboratorio Inmunología, Hospital Del Salvador, SANTIAGO, Chile
Background/Purpose: Interstitial Lung Disease (ILD) is a common manifestation of Connective Tissue Diseases (CTD), mainly Systemic sclerosis (SSc), Rheumatoid Arthritis and Idiopathic Inflammatory Myositis (IIM)…
Abstract Number: 1344 • 2018 ACR/ARHP Annual Meeting
Anti-Splicing Factor Proline/Glutamine-Richautoantibodies Rarely Co-Exist with Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies in a Cohort of Dermatomyositis Patients from the United States
Yuji Hosono¹, Iago Pinal-Fernandez¹, Katherine Pak¹, Jemima Albayda², Eleni Tiniakou³, Julie J. Paik⁴, Christopher A. Mecoli⁵, Sonye K. Danoff⁶, Lisa Christopher-Stine⁶ and Andrew Mammen^1,7, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Internal Medicine/Rheumatology, Johns Hopkins University, Baltimore, MD, ⁶Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Neurology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5) autoantibodies are common among Japanese dermatomyositis (DM) and clinically amyopathic DM (CADM) patients who develop rapidly progressive interstitial lung…
Abstract Number: 2144 • 2017 ACR/ARHP Annual Meeting
Multiple Serum Cytokine and Chemokine Profiling to Identify Combinational Biomarkers Toward Patients of Polymyositis/Dermatomyositis Complicated with Rapidly Progressive Interstitial Lung Disease
Toshimasa Shimizu¹, Tomohiro Koga^1,2, Yoshiro Horai³, Keita Fujikawa⁴, Yushiro Endo¹, Sousuke Tsuji¹, Ayuko Takatani¹, Masataka Umeda¹, Shoichi Fukui¹, Remi Sumiyoshi¹, Ayako Nishino¹, Shinya Kawashiri¹, Naoki Iwamoto¹, Takashi Igawa¹, Kunihiro Ichinose¹, Mami Tamai¹, Noriho Sakamoto⁵, Hideki Nakamura¹, Tomoki Origuchi⁶, Hiroshi Mukae⁵, Masataka Kuwana⁷ and Atsushi Kawakami¹, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Center for Bioinformatics and Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Japan, ³Department of Rheumatology, National Hospital Nagasaki Medical Center, Nagasaki, Japan, ⁴Japan Community Health care Organization Isahaya General Hospital, Nagasaki, Japan, ⁵Department of RespiratoryMedicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁶Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan, ⁷Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Polymyositis (PM)/dermatomyositis (DM) is a chronic inflammatory disorders involved in skeletal muscles. Interstitial lung disease (ILD) complicated with PM/DM patients is often developed as…
Abstract Number: 2376 • 2015 ACR/ARHP Annual Meeting
Clinical Features in Dermatomyositis Patients with Novel Autoantibody to Small Ubiquitin-like Modifier Activating Enzymes (Anti-SAE Antibody) and Relationship to Interstitial Lung Disease: A Systematic Review of 29 Cases
Sirada Panupattanapong¹, Jessica Sun² and Kevin Baszis¹, ¹Pediatrics, Division of Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO, ²Pediatric, Division of Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO
Background/Purpose: Anti-SAE antibody is a novel myositis-specific antibody first described in 2007. SAE is an enzyme that facilitates sumoylation, leading to the formation of stable…
Abstract Number: 304 • 2015 ACR/ARHP Annual Meeting
Abnormal Pulmonary Function Tests, Interstitial Lung Disease, and Lung Function Decline in Patients with Classic and Clinically Amyopathic Dermatomyositis
Michael George¹, Maryl Kreider², Rupal Shah², Wallace Miller Jr.³, Peter A. Merkel⁴ and Victoria Werth^5,6, ¹Department of Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Pulmonary, Allergy & Critical Care, University of Pennsylvania, Philadelphia, PA, ³Radiology, University of Pennsylvania, Philadelphia, PA, ⁴Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵Dermatology, Veterans Affairs Medical Center, Philadelphia, PA, ⁶Dermatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Interstitial lung disease (ILD) is common in classic dermatomyositis (DM) and clinically amyopathic dermatomyositis (CADM), in which rash is present without weakness. Previous studies…
Abstract Number: 2366 • 2015 ACR/ARHP Annual Meeting
The Anti-MDA5 Autoantibody Phenotype: Defining Clinical, Biochemical and Radiological Features Suggestive of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease
Sabrina Hoa¹, Yves Troyanov¹, Marvin J. Fritzler², Ira N. Targoff³, Anne-Marie Mansour¹, Eric Rich¹, Hind Boudabbouz¹, Josiane Bourré-Tessier¹, Sandra Chartrand¹, Marianne Landry¹, Martin Albert¹ and Jean-Luc Senécal¹, ¹Université de Montréal, Montreal, QC, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³Veterans Affairs Medical Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Anti-MDA5 autoantibody associated syndrome is a novel entity within the spectrum of autoimmune myositis. It has been described as a clinical mimic of the…
Abstract Number: 2371 • 2015 ACR/ARHP Annual Meeting
The Clinical Features of Recurrent Interstitial Lung Disease in Dermatomyositis Patients with Anti- Melanoma Differentiation-Associated Gene 5 Antibody
Yuji Hosono¹, Ran Nakashima¹, Kosaku Murakami², Yoshitaka Imura², Naoichiro Yukawa², Hajime Yoshifuji², Koichiro Ohmura² and Tsuneyo Mimori², ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Department of Rheumatology and Clinical Immunology, Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Interstitial lung disease (ILD) is the most common cause of mortality in polymyosytis (PM) and dermatomyositis (DM). It is well known that the DM…
Abstract Number: 1260 • 2014 ACR/ARHP Annual Meeting
The Early Use of Cyclosporine Is Beneficial for Long-Term Prognosis in Patients of Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease with Anti- Synthetase Antibodies
Yuji Hosono¹, Ran Nakashima², Yoshitaka Imura³, Naoichiro Yukawa², Hajime Yoshifuji², Takaki Nojima⁴, Koichiro Ohmura² and Tsuneyo Mimori², ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁴Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan
Background/Purpose: Interstitial lung disesases (ILD) is the most common cause of mortality in polymyosotis (PM) and dermatomyositis (DM). Cyclosporine had been reported to improve clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].